ASH 2022 | Matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2L treatment of R/R LBCL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, briefly shares the results of a matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in the second-line treatment of patients with relapsed/refractory (R/R) large B-cell lymphoma (LCBL). Overall, the study found that data for the key primary and secondary efficacy endpoints were similar, but the rate of adverse events was lower in patients treated with liso-cel. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
TG Therapeutics: Consultancy, Research Funding; Genentech: Consultancy, Other: DMC, Research Funding; Novartis: Research Funding; Abbvie: Consultancy; AstraZeneca: Consultancy; BMS: Consultancy; Adaptive Technologies: Consultancy; ADC Therapeutics: Consultancy; Beigene: Consultancy; Impact Bio: Consultancy; SeaGen: Speakers Bureau; Celgene: Other: DMC.
